AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 142 min read$TNGX

Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics

Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G for Tango Therapeutics Inc. reporting a 6.0% beneficial stake in Tango common stock. The filing cites aggregate beneficial ownership of 9,742,402.80 shares, with shared voting power over 9,740,098.80 shares and shared dispositive power over 9,740,206.80 shares.

Original reporting
stocktitan.net
Published Aug 14, 2026, 6:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 7:41 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TNGX
Neutral
medium confidence
Mentioned
$TNGX
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TNGXNeutralLow
01

Why it matters

The disclosure updates the market on a 6.0% beneficial stake and shared voting/dispositive power, which can matter for governance optics but does not describe any new corporate action by Tango.

02

Market read

Traders may monitor for follow-on 13D/13G amendments or any governance-related developments, but the article itself contains no such catalyst.

03

What to watch

The filing disclaims beneficial ownership for certain client accounts/entities, so the effective economic exposure may differ from the headline aggregate figures.

Relevance 4/10Novelty 5/10Timing: filing dated 06/30/2026, reported in article on 2026-08-14

Background

The article summarizes a Schedule 13G beneficial ownership filing by The Goldman Sachs Group and Goldman Sachs & Co. LLC for Tango Therapeutics.

Company-level read

Ticker impact

$TNGXNeutralMedium confidence
Context

Goldman Sachs disclosed a Schedule 13G stake of 6.0% in Tango Therapeutics, with shared voting and dispositive power over ~9.74M shares.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven around ownership optics rather than fundamentals.

Evidence & confidence

The filing provides ownership percentage and shared control details, with no accompanying deal, financing, or company-specific fundamental update.

Market effects

Sector

No direct sector read-through; this is a single-issuer ownership disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 13G stake is often passive or client-driven and may not translate into active influence, so price impact may be overstated.

Key entities

  • issuer
    Tango Therapeutics, Inc.

    Subject of the Schedule 13G beneficial ownership disclosure, with Goldman reporting 6.0% beneficial ownership.

  • reporting_person
    The Goldman Sachs Group, Inc.

    Parent holding company reporting beneficial ownership on the Schedule 13G.

  • reporting_person
    Goldman Sachs & Co. LLC

    Broker-dealer and investment adviser subsidiary reporting shared voting and dispositive power.

Read at source← All news

Related articles

AUG 11
$TNGXMed

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.

investing.com4 min
AUG 11
$TNGXMed

Tango Therapeutics, Inc. (TNGX): Results of Operations and Financial Condition

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tngx-ex99_1.htm EX-99.1 EX-99.1 Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer foll

SEC EDGAR 8-K4 min
JUL 15
$TNGXMed

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

Canaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.

yahoo.com5 min
JUN 8
$TNGXMedAI 9/10

Tango Therapeutics Announces Proposed $500 Million Public Offering

Tango Therapeutics (Nasdaq: TNGX) announced a proposed underwritten public offering of $500 million of its common stock, with all shares to be sold by the company. The underwriters may be granted a 30-day option to buy up to an additional $75 million of shares. J.P. Morgan, Leerink Partners, Cantor and Stifel are joint bookrunners.

manilatimes.net4 min
JUN 8
$TNGXHighAI 8/10

Tango's Combo Therapy Shows 92% Response In Pancreatic Cancer; Stock Up

Tango Therapeutics (TNGX) shares rose after early Phase 1/2 results for Vopimetostat plus Revolution Medicines’ RAS(ON) inhibitor Daraxonrasib in MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma. The company reported a 92% objective response rate; at six months, 90% were progression-free and median PFS was not reached. Both regimens were generally well tolerated, and Tango plans Phase 3 first-line development later in 2026.

rttnews.com4 min